{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-002038","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2022-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.998742+00:00","generated_at":"2026-06-27T13:16:11.561678+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Techne Q2 FY2022: GAAP EPS $1.94, adj EPS $1.88; rev $269.3M; $0.32 dividend, $400M buyback","bullets":["Organic revenue +17% to $269.3M; Protein Sciences organic growth 19% with ProteinSimple up 27% and GMP Proteins >180%.","GAAP EPS $1.94 vs $1.15 YoY; record adjusted EPS $1.88 vs $1.62 YoY.","Adjusted operating income $102.8M, margin 38.3%; up 18% YoY.","Board declared $0.32 quarterly dividend, payable Feb 25, 2022 to holders of record Feb 11, 2022.","New $400M share repurchase program approved, replacing prior program, effective Feb 2, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-002038","json":"https://secwatch.observer/filing/0001437749-22-002038.json","markdown":"https://secwatch.observer/filing/0001437749-22-002038.md","text":"https://secwatch.observer/filing/0001437749-22-002038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000143774922002038/0001437749-22-002038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000143774922002038/tech20220131_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:16:11.561678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}